The incidence of relapse during the 6-months double-blind follow-up period was 17% and 29% for duloxetine and placebo, respectively.
Retsidiivide esinemissagedus 6- kuulise topelt- pimeda jälgimisperioodi jooksul oli duloksetiini ja platseebo rühmas vastavalt 17% ja 29%.